Related Experiment Video
Updated: Jun 8, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as
Neil Johnson1, Geoffrey I Shapiro
1Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA 02215, USA.
Importance Of The Field:
The eukaryotic cell division cycle is a tightly regulated series of events coordinated by the periodic activation of multiple cyclin-dependent kinases (cdks). Small-molecule cdk-inhibitory compounds have demonstrated preclinical synergism with DNA-damaging agents in solid tumor models. An improved understanding of how cdks regulate the DNA damage response now provides an opportunity for optimization of combinations of cdk inhibitors and DNA damaging chemotherapy agents that can be translated to clinical settings.
Areas Covered In This Review:
Here, we discuss novel work uncovering multiple roles for cdks in the DNA-damage-response network. First, they activate DNA damage checkpoint and repair pathways. Later their activity is turned off, resulting in cell cycle arrest, allowing time for DNA repair to occur. Recent clinical data on cdk inhibitor-DNA-damaging agent combinations are also discussed.
What The Reader Will Gain:
Readers will learn about novel areas of cdk biology, the complexity of DNA damage signaling networks and clinical implications.
Take Home Message:
New data demonstrate that cdks are 'master' regulators of DNA damage checkpoint and repair pathways. Cdk inhibition may therefore provide a means of potentiating the clinical activity of DNA-damaging chemotherapeutic agents for the treatment of cancer.
Insights
Cyclin-dependent kinases (cdks) are master regulators of DNA repair pathways. Inhibiting cdks can enhance the effectiveness of DNA-damaging chemotherapy agents for cancer treatment.
Area of Science:
- Cell Biology
- Molecular Oncology
- Cancer Therapeutics
Background:
- The eukaryotic cell cycle is regulated by cyclin-dependent kinases (cdks).
- Cdk inhibitors show preclinical synergy with DNA-damaging agents in solid tumors.
- Understanding cdk roles in DNA damage response optimizes combination therapies.
Purpose of the Study:
- To review novel roles of cdks in the DNA damage response network.
- To discuss the activation and inactivation of cdks during DNA repair.
- To examine clinical data on cdk inhibitor-DNA-damaging agent combinations.
Main Methods:
- Review of recent research on cdk biology and DNA damage signaling.
- Analysis of the regulatory roles of cdks in DNA damage checkpoints and repair.
- Discussion of clinical trial outcomes for combination therapies.
Main Results:
- Cdks are identified as key regulators of DNA damage checkpoint and repair pathways.
- Cdk activity is dynamically regulated, enabling cell cycle arrest for DNA repair.
- Novel insights into cdk biology and DNA damage signaling complexity are presented.
Conclusions:
- Cdks act as master regulators of DNA damage response pathways.
- Cdk inhibition offers a strategy to potentiate DNA-damaging chemotherapy.
- This approach holds promise for improving cancer treatment efficacy.
More Related Videos
08:21Cell Cycle-specific Measurement of γH2AX and Apoptosis After Genotoxic Stress by Flow Cytometry
Published on: September 1, 2019
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity
Inhibition of CDK Activity
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle